What is the BCT.TO share price today?

This page shows the latest available BriaCell Therapeutics Corp. (BCT.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is BriaCell Therapeutics Corp. listed?

BriaCell Therapeutics Corp. trades on the Toronto Stock Exchange under the symbol BCT.TO, ISIN CA1079303071.

How large is BriaCell Therapeutics Corp.?

Its market capitalisation is approximately 43.85M CAD, based on the latest available price and share count from our data provider.

Toronto Stock Exchange (TSX) · BCT.TO · ISIN CA1079303071

BriaCell Therapeutics Corp.

5.91 CAD

−0.01(−0.17%)

Previous close · Sep 18, 15:59 ET

Data last updated: Sep 18, 15:59 ET (22 h ago)· Delayed exchange data

BriaCell Therapeutics Corp. (BCT.TO) trades on the Toronto Stock Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 43.85M CAD. The company reports around 17 employees. Its ISIN is CA1079303071. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Checking today's session…

Key facts

Exchange

Toronto Stock Exchange (TSX)

ISIN

CA1079303071

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

51.42M CAD

Employees

Previous close

5.92 CAD

Day range

5.73 – 6.11

52-week range

3.68 – 20.40

Volume

15.64K

50-day average

5.09 CAD

200-day average

6.31 CAD

Asset type

Equity

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently undergoing Phase I/IIa clinical trials, where it is being evaluated in combination with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, an accessible, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test designed to determine patients' HLA types. BriaCell has established a non-exclusive clinical trial collaboration with Incyte Corporation to assess the effects of combining novel therapeutic candidates. Additionally, it holds a cooperative research and development agreement with the National Cancer Institute for preclinical studies to advance and test Bria-OTS cellular immunotherapy as a cancer treatment. The company's headquarters are situated in West Vancouver, Canada.

Company website

Frequently asked

What is the BCT.TO share price today?: This page shows the latest available BriaCell Therapeutics Corp. (BCT.TO) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is BriaCell Therapeutics Corp. listed?: BriaCell Therapeutics Corp. trades on the Toronto Stock Exchange under the symbol BCT.TO, ISIN CA1079303071.
How large is BriaCell Therapeutics Corp.?: Its market capitalisation is approximately 43.85M CAD, based on the latest available price and share count from our data provider.

All BriaCell Therapeutics Corp. data comes from exchange and provider feeds for the Toronto Stock Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.